Skip to main content

Table 2 Preprandial plasma glucose levels

From: Risk of hypoglycemia associated with repaglinide combined with clopidogrel, a retrospective cohort study

Preprandial plasma glucose

Repaglinide and clopidogrel group

Mitiglinide and clopidogrel group

Repaglinide group

(N = 15)

(N = 15)

(N = 15)

Breakfast

 Before starting glinide

180.1 ± 35.5

161.8 ± 38.0

151.0 ± 20.9

 After starting glinide

136.5 ± 44.1

150.1 ± 41.3

127.8 ± 33.0

 Decrease in the amplitude of glycemic excursions

43.6 ± 33.6 *

11.6 ± 30.0

23.2 ± 23.7

Lunch

 Before starting glinide

228.2 ± 48.6

231.7 ± 48.7

196.1 ± 32.3

 After starting glinide

178.8 ± 69.8

177.2 ± 53.9

168.7 ± 37.2

 Decrease in the amplitude of glycemic excursions

50.0 ± 36.6

55.8 ± 43.3

27.4 ± 38.9

Dinner

 Before starting glinide

193.3 ± 54.5

190.5 ± 47.6

186.8 ± 56.5

 After starting glinide

131.6 ± 43.4

165.9 ± 44.6

144.3 ± 52.8

 Decrease in the amplitude of glycemic excursions

61.6 ± 49.3

24.6 ± 45.0

42.5 ± 38.9

  1. Mean ± S.D., * p < 0.05 for the “repaglinide and clopidogrel group” versus the “mitiglinide and clopidogrel group”